Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma



Status:Completed
Conditions:Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 30
Updated:10/25/2018
Start Date:January 2012
End Date:August 2012

Use our guide to learn which trials are right for you!

Randomized Controlled Trial of Marine Lipid Fraction PCSO-524™ on Airway Inflammation and Hyperpnea-Induced Bronchoconstriction in Asthma

The primary aim of this study will be to evaluate the effects of Lyprinol® supplementation on
airway inflammation and the bronchoconstrictor response to dry air hyperpnea in individuals
with asthma. The investigators hypothesize that Lyprinol® supplementation, compared to
placebo, will significantly attenuate airway inflammation and hyperpnea-induced
bronchoconstriction in asthmatic individuals.

Our research group has shown, on numerous occasions that fish oil has a markedly protective
effect in suppressing airway inflammation and exercise-induced bronchoconstriction in elite
athletes and asthmatic individuals. Purified fish oil and the marine lipid fraction PCSO-524™
(Lyprinol™) have both been used in supplementation studies in asthma [2, 10, 11]. While fish
oil is a rich source of the omega-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), Lyprinol® is a patented extract of stabilized lipids from the New
Zealand green-lipped mussel, Perna canaliculus, combined with olive oil and vitamin E. EPA
and DHA are the main ingredients of fish oil, and thus there will be similarities between
Lyprinol and fish oil in terms of mechanism of action. Thus, we are aiming to show that
Lyprinol® can modulate these inflammatory eicosanoids to exert anti-inflammatory effects.

Inclusion Criteria:

- Have been diagnosed with asthma and EIB. Evidence of a diagnosis of asthma will
include medication use as well as history and symptoms as outlined in the NHLBI
Guidelines for the Diagnosis and Management of Asthma. For the diagnosis of EIB,
subjects must demonstrate a fall in FEV1 of ≥ 10% after dry air eucapnic voluntary
hyperventilation (EVH), a simulated exercise challenge; FEV1 is a measure of lung
function

- Not currently be taking any fish oil supplements

- Limit their fish consumption to 1 fish meal per week during the course of the study

Exclusion Criteria:

- Severe asthma is indicated. These subjects will be identified by a post-EVH drop in
FEV1 that is greater than 50% during their first lab testing session or will have a
history of severe asthma-related events such as hospitalizations or emergency room
visits. Only mild to moderate asthmatics (i.e. subjects whose FEV1 drops by 10-50%)
will be included in this study.

- They taking currently taking asthma maintenance medications

- They are pregnant

- They have a history of hyperlipidemia (high cholesterol), hypertension, diabetes,
bleeding disorder, delayed clotting time, or seizure disorder

- They are allergic to shellfish, fish, corn, or soy products
We found this trial at
1
site
?
mi
from
Bloomington, IN
Click here to add this to my saved trials